Mursla Bio, a pacesetter in Extracellular Vesicle (EV) science on a mission to considerably enhance most cancers outcomes for at-risk sufferers by means of the ability of dynamic biopsy expertise, as we speak introduced outcomes of its multi-center medical research, MEV01, in collaboration with main tutorial institutes together with College School London, Imperial School London, College Hospital of Santa Maria and the Medical College of Graz.
The continuing research is investigating the Firm’s dynamic biopsy-based blood check, EvoLiver™, for the surveillance of major liver most cancers, Hepatocellular Carcinoma (HCC), amongst high-risk, cirrhotic sufferers. Mursla Bio established the primary EV multiomics biomarker signature for HCC with 86% early-stage sensitivity and 88% specificity, considerably surpassing present surveillance strategies together with ultrasound and alpha-fetoprotein testing.
The outcomes are a part of MEV01 and primarily based on 464 affected person samples, primarily collected prospectively, inside a western inhabitants, representing etiologies comparable to MASH / fatty liver illness, alcoholic liver illness and hepatitis. Mursla Bio developed the EvoLiver check by isolating organ-specific hepatocyte extracellular vesicles (h-EVs) from blood samples, enabling the validation of a novel HCC biomarker signature comprised of fewer than 10 h-EV microRNAs and proteins.
The increasing inhabitants liable to growing HCC is inserting an growing financial burden on healthcare methods because of present surveillance strategies, together with ultrasound, which typically have difficulties detecting small tumors particularly in obese sufferers. An reasonably priced, blood-based surveillance instrument with considerably improved sensitivity would remodel affected person outcomes given the prevailing remedy choices. Figuring out HCC-specific blood biomarkers stays difficult as a result of complexity of liver illness and the issue in detecting diverse etiologies.
EvoLiver leverages a pioneering platform that isolates h-EVs, identifies and validates novel multiomics biomarkers to tell apart HCC with cirrhosis from non-cancerous cirrhosis. EvoLiver’s low blood quantity requirement and fast turnaround occasions help improved affected person outcomes whereas streamlining illness administration for clinicians and sufferers. The corporate’s subsequent steps with EvoLiver are to publish ultimate MEV01 ends in 2025, provide the check within the US as a Laboratory Developed Check (LDT), and arrange a bigger research to safe FDA approval and broad reimbursement protection.
Our flagship check has proven that our pioneering technique of non-invasively capturing dynamic mobile processes from particular tissues by way of organ-specific EVs can detect early-stage HCC with far higher sensitivity than customary strategies. Earlier detection is essential to enhancing survival charges, because it allows entry to efficient therapies comparable to ablation, resection, or transplant. Our blood modality can be a extra handy technique that can improve affected person adherence to surveillance testing. EvoLiver represents an essential step ahead in the way in which liver most cancers is detected and monitored.”
Pierre Arsène, Founder and CEO, Mursla Bio
Mursla Bio’s dynamic biopsy expertise combines the accuracy and illness sub-typing capabilities of tissue biopsies with the convenience of liquid biopsy pattern assortment, offering a non-invasive intervention with complete organic insights. That is made doable by superior EV science and an revolutionary extracellular omics method, supported by Mursla Bio’s applied sciences. These applied sciences embody organ-specific EV isolation from biofluids for exact focusing on, an AI-enabled multi-omics workflow for illness biomarker identification, and a scalable assay platform utilizing optimum biomarkers for medical use.
Dr Tomás Dias, Mursla Bio’s CSO, introduced information from the research at one of many largest medical conferences, AASLD’s The Liver Assembly, in San Diego, on 17 November 2024 in a presentation titled: “Novel multiomics biomarker signature derived from blood circulating hepatocyte-extracellular vesicles for the early detection of HCC”.
